Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits
MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that
MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the
exact effect of MMI-166 on human pancreatic cancer.
Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human
pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human
pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.
Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990
pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of
apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.
Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.